Gastroenterology Clinical Research

Crohn's Disease Trial Feasibility: The Referral Pathway Matters as Much as the Investigator

A Crohn's disease research site needs more than an IBD patient list or an experienced investigator. Its referral pathway must turn protocol fit into timely screening.

A clinician and research coordinator reviewing a study visit plan with an adult patient in a bright clinical consultation room.

An experienced inflammatory bowel disease investigator is an important part of Crohn's disease trial feasibility. Yet an impressive investigator biography does not tell a sponsor how a person living with Crohn's reaches the research team, whether their recent treatment history is available, or whether a referral can turn into a timely, informed screening decision.

For sponsors and CROs, the more useful question is not simply, 'How many Crohn's patients do you have?' It is, 'Who sees them, what information can be checked appropriately before an approach, and who owns each handoff from physician referral to the research visit?' A site can have clinical expertise and still lose its enrollment window through fragmented referrals.

Treat Crohn's as a referral network, not a single database

Crohn's disease may affect different parts of the digestive tract and may require a combination of laboratory tests, endoscopy and imaging for clinical assessment. NIDDK explains that diagnosis and evaluation are not based on one test alone. That matters to feasibility because a diagnosis code rarely establishes the specific disease activity, treatment history or anatomical findings a research protocol requires.

Potential participants may be followed by a community gastroenterologist, an advanced IBD specialist, a primary care physician or more than one practice. A defensible plan identifies which relationships are active and whether those clinicians are able and willing to discuss appropriate research opportunities. Counting every record associated with the referral network as if it were immediately available to a site would overstate access.

Ask for a route map rather than a number: where a possible participant is first identified, who reviews the protocol's prescreenable criteria, how permission for contact is obtained, who introduces the study, and how the coordinator receives a referral. The site should distinguish an established two-way clinical relationship from an aspirational referral partnership. WCR's gastroenterology program describes private-practice referral pathways and coordinated local procedure access, subject to each study's actual requirements.

Review treatment history before promising enrollment

Crohn's protocols can differ sharply in prior exposure to biologic agents or other advanced therapies, treatment response, concomitant medications, steroid restrictions and washout periods. Some studies need objective evidence of active inflammation even when symptoms suggest a flare. The investigator must ultimately apply the complete current protocol; a coordinator's early review can only identify people who might merit formal assessment.

The FDA's April 2022 draft guidance on drug development for Crohn's disease addresses trial populations, efficacy measures and safety considerations. It is draft guidance, not a substitute for protocol-specific eligibility. The operational lesson is to identify the decisive criteria early. A site with many Crohn's diagnoses but limited access to medication histories may need additional confirmation before giving a recruitment forecast.

During feasibility, ask for the share of potential referrals with recent gastroenterology follow-up, accessible treatment chronology and likely willingness to attend the proposed study visits. Do not convert those estimates into randomized participants without allowing for contactability, consent, formal screening and screen failures. This is especially important when competing IBD studies draw from the same clinicians and patients.

Check what investigator experience actually documents

A publication can be useful evidence of therapeutic exposure, but the credit needs to be described correctly. There is a meaningful difference between a principal manuscript author, a named abstract author, a study-group collaborator and an investigator listed in a supplemental appendix. None of these roles alone proves that a location currently has adequate staff time or a recruitment population for a new protocol.

WCR has publicly documented that Dr. Lucky Flores was listed in the investigator supplement for the Phase 2 mirikizumab Crohn's disease study published in Gastroenterology, while the main manuscript author list is separate. WCR has also documented a 2020 Gastroenterology conference abstract naming Dr. Flores and Dr. Gustavo Albizu-Angulo as authors of work concerning ustekinumab and Crohn's disease with autoimmune skin manifestations. These are different types of published contributions, and they should not be represented as identical evidence.

For a site-selection team, the next step is practical: speak with the proposed principal investigator about the particular disease phenotype, past treatment exclusions, endoscopic measures, adverse-event follow-up and delegation of responsibilities. Verify which investigator will be available for screening decisions and which GI clinicians or procedure partners will support the specific site. Publication history starts the conversation; the protocol and current resources determine fit.

Make the referral-to-screening handoff visible

Many failed referrals are not failures of medical eligibility. The referring office may not know whom to contact, a patient may be offered an appointment they cannot attend, or the research team may lack the records needed to judge whether a screening visit is reasonable. These are manageable process problems if the responsibilities are made explicit.

A useful workflow includes one clinical contact for questions, a coordinator responsible for referral follow-up, a secure and authorized process for receiving relevant documents, a way to record each referral outcome, and a rapid escalation route when a physician identifies time-sensitive clinical concerns. Referral and treatment decisions must remain with appropriately qualified clinicians. Research contact should follow the approved consent and privacy procedures rather than treating every referral as automatic enrollment.

Sponsors should ask for a short example of how the site handles a referral that initially looks eligible but has incomplete biologic history. The answer should identify the information owner and next decision, not promise that every gap will be solved within a fixed number of days.

Test the assessment pathway and participant burden together

Some Crohn's trials use endoscopy with scoring or central reading, stool or blood biomarkers, imaging, biopsies or specific visit windows. Not every protocol needs every assessment. A sponsor should map the required procedures against the actual local services, clinician availability, turnaround times and sample workflows before relying on an enrollment estimate.

Coordinated access does not mean on-site ownership of each procedure. When a procedure is performed with an outside provider, confirm who schedules it, who gives preparation instructions, how images and samples reach the intended readers or laboratories, and what happens if a visit must be repeated. The same map should account for travel, work schedules, potential discomfort and bilingual instructions where relevant.

This operational review differs from simply checking whether a colonoscopy is possible. It asks whether the referral, necessary clinical assessment, consent and ongoing study visits form a realistic sequence for the individual participant. For comparison, our separate ulcerative colitis site-selection article examines protocol-specific procedure coordination in more depth.

A Crohn's site-feasibility decision framework

A sponsor or CRO can use the following questions to reach a conditional go, no-go or further-evidence decision. Record the answer, its evidence, the responsible person and what remains unknown.

  • Referral access: Which named practices routinely refer Crohn's patients, and how is each relationship used without inflating unique patient counts?
  • Protocol fit: Which inclusion and exclusion rules can be reviewed from authorized records, and which require a formal screening procedure?
  • Investigator role: What disease-specific experience is documented, and who makes eligibility and safety decisions for this protocol?
  • Availability: How do active competing trials and standard-care appointments affect the same patient pool and clinician time?
  • Assessment access: Who controls any required endoscopy, imaging, specimens, reading and scheduling dependencies?
  • Conversion: How are referrals, contacted prospects, consent, screening, screen failures and randomization tracked separately?
  • Participant experience: Who handles language needs, visit preparation, travel complications and follow-up after a missed appointment?

How WCR would assess a new Crohn's opportunity

Wellness Clinical Research coordinates clinical research operations in Miami Lakes, Florida, and Vega Baja, Puerto Rico. Publicly described capabilities include gastrointestinal and multi-specialty investigator experience, private-practice referral relationships, bilingual communication, specimen handling and coordinated local access to endoscopy and imaging. Availability and physical location of any required service must be confirmed for the proposed protocol and site.

A realistic Crohn's feasibility review begins with the full eligibility criteria and schedule of activities, then checks the proposed investigator, current referral route, treatment-history access, assessment partners, competing study obligations and participant visit burden. Historic investigator publications are relevant context, not an enrollment promise. The outcome may be favorable, unfavorable or conditional on resolving specific dependencies.

Sponsors and CROs can submit a study opportunity for protocol-specific review. That conversation is most useful when it includes the target population, prior-therapy requirements, required procedures and actual enrollment window. Clear assumptions help both teams decide whether a study belongs at the site.

Sources and further reading

Continue exploring

More from Wellness Clinical Research